You are here

SQI DIAGNOSTICS’ PARTNER LAUNCHES TWO NEW DIRECT-TO-CONSUMER TESTS
Toronto, Ontario
January 28, 2019
SQI Diagnostics Inc. (“SQI Diagnostics” or the “Company”) (TSX-V: SQD; OTCQB: SQIDF),

a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics (“SQI” or the “Company”), today announces two new product launches within the imaware™ family of at-home tests by its partner, Microdrop. The new tests, which are now available for purchase, measure markers for rheumatoid arthritis and a test to monitor already-diagnosed celiac disease patients, a complement to the previously announced celiac screening test.

Rheumatoid arthritis afflicts 1% of the world’s population, with millions of people newly diagnosed each year in North America alone. The new RA test from SQI Diagnostics sold by Microdrop’s imaware™ platform gives patients information they can use to talk to their doctor about diagnosis and treatment of a disease in which early identification and treatment is most effective.

As a follow-up to the imaware™ celiac screening test introduced last month, Microdrop has launched a celiac disease monitoring service, which allows someone to purchase a subscription to be continuously monitored, all at-home, to determine if their diet and treatment is effective and sustaining. These tests will be run using SQI’s proprietary test kits and automated analysis systems.

“Being the technological cornerstone of Microdrop’s imaware™ product portfolio is exciting for SQI,” said Andrew Morris, CEO of SQI Diagnostics. “These two new services from Microdrop utilizing SQI technology are a testament to the success and unique ability for SQI to meet the needs of its partners and their customers in the lab testing market.”

Run on SQI’s automated systems, the imaware™ at-home testing product portfolio, for which SQI is the exclusive provider, addresses a current unmet need in the market today. The effectiveness of the imaware™ tests have been validated by top opinion leaders and celiac and autoimmune medical doctors.

With more direct-to-consumer tests from imaware™ and SQI coming in 2019 and beyond, the goal of giving patients the opportunity to be more well-informed about their health becomes more of a reality. All three current at-home tests are now shipping to consumers, and can be purchased online at imaware.health.

About imaware™

imaware™ is a digital platform that allows patients to order an at-home testing kit online, and mail back their sample for lab processing. The tests are processed by a CLIA certified laboratory and results are available to patients within 72 hours. The accurate online results empower patients to take control of their health and share these results with their doctor. For more information, please visit imaware.health

Media Contact:

Nicholas Olteanu, CEO
nick@imaware.health

About SQI Diagnostics

SQI Diagnostics is a life sciences and diagnostics company that develops clinical grade multiplexed microarray and molecular assays run on its automated instrumentation for the pharmaceutical research, animal health, and clinical diagnostics markets. SQI develops custom research and diagnostic assays that are multiplexed; meaning the simplification, consolidation and automation of many individual tests into one. This increases sample throughput, reduces time, cost and chance for human error, and provides excellent data quality. For more information, please visit sqidiagnostics.com.

Sales and Marketing Contact:

Vice President, Global Commercial Operations
Russ Peloquin
913.484.9022
rpeloquin@sqidiagnostics.com

SQI Investor Relations Contacts:

Chief Executive Officer
Andrew Morris
416.674.9500 ext. 229
amorris@sqidiagnostics.com

Vice President, Finance and Administration
Patricia Lie
416.674.9500 ext. 277
plie@sqidiagnostics.com

Forward-looking Information

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “believe”, “in the process”, “is subject to” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the ability of our patents to adequately protect our rights or permit us to gain or keep any competitive advantage, and our ability to market and sell our novel multiplexing technologies and detection platforms. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.